Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

The Lancet. Oncology - 1 Jun 2011

De Roock Wendy, De Vriendt Veerle, Normanno Nicola, Ciardiello Fortunato, Tejpar Sabine

Abstract excerpt

The discovery of mutant KRAS as a predictor of resistance to epidermal growth-factor receptor (EGFR) monoclonal antibodies brought a major change in the treatment of metastatic colorectal cancer. This seminal finding also highlighted our sparse knowledge about key signalling pathways in colorectal tumours. Drugs that inhibit oncogenic alterations such as phospho-MAP2K (also called MEK), phospho-AKT, and mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to MAP Kinase Kinase 1

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins p21(ras)

Share to PTEN Phosphohydrolase

Share to ras Proteins

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 21163703
DOI: 10.1016/S1470-2045(10)70209-6

Genes

EGFR
KRAS
BRAF
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.PMID 21163703Read ↗

EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy.Semantic proximity Read ↗

KRAS mutations in metastatic colorectal cancer: from a de facto ban on anti-EGFR treatment in the past to a potential biomarker for precision medicine.Semantic proximity Read ↗

KRAS inhibition in metastatic colorectal cancer: An update.Semantic proximity Read ↗

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.Semantic proximity Read ↗

The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status.Semantic proximity Read ↗

New strategies for treatment of KRAS mutant metastatic colorectal cancer.Semantic proximity Read ↗

KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents.Semantic proximity Read ↗

Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities.Semantic proximity Read ↗

Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer.Semantic proximity Read ↗

Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review.Semantic proximity Read ↗

KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.